Longerterm data from STEP5 showed that a ~15% mean weight loss with semaglutide 2.4 mg could be maintained over two years, contrasting with typical weight regain patterns after dietonly interventions
From this treatment difference we can deduce that GIP-R agonism contributes considerably to the global efficacy of TZP
We personalize dosing and coaching to your goalsfat loss, waist change, improved labswhile monitoring comfort and safety
We build your eating around protein and add a little strength work, because that is what keeps your muscle, and your metabolism, while the fat comes off
Leptin resistance develops again over months, meaning your brain becomes less responsive to signals that you have adequate energy stores
Presented for research literature review only Williams DM et al